Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a study of oral LEO 22811 in psoriasis vulgaris
2009-017858-12Phase 2Completed
- Sponsor
- LEO Pharma
- Start
- Mar 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of LEO 22811 in plaque psoriasis (4 arms), sponsored by LEO Pharma. Primary endpoint: Percentage change in PASI from baseline to Week 12. Started Mar 2010; status: completed.
02
Drugs
LEO 22811
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on 2009-017858-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-017858-12.